

# Antibodies Against CGRP in Migraine Treatment



**Alan M. Rapoport**

The David Geffen School of Medicine at UCLA

---

The status of small molecule CGRP receptor antagonists will be discussed. None have come to market in the last 10 years although all have been found to be effective acute care treatments for migraine.

About 3 years ago work began on monoclonal antibodies to CGRP and 4 companies are already in phase 3 trials. All 4 have shown positive results for migraine prevention. Three of them target the CGRP ligand and one the CGRP receptor. One has already been studied for chronic migraine with a novel endpoint of reduced hours of headache at month 3 when compared with baseline. This is a positive study which shows very early efficacy.

Three are given by subcutaneous injection one or two times per month. One was studied only as an intravenous injection which appears to work for up to 6 months. There are few side effects caused by any of the preparations and no liver toxicity. One exciting finding is the 100% responder rate in higher than 15% when it has been evaluated.

There will be a detailed description of the primary and secondary endpoints as well as adverse events.

---